IMPLANT SITE HYPERTROPHY

IMPLANT SITE HYPERTROPHY was reported 9 times

IMPLANT SITE HYPERTROPHY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Polyene Antifungal [EPC] 1 0.0000
1 Progestin [EPC] 3 0.0000
2 Calcineurin Inhibitor Immunosuppressant [EPC] 1 0.0000
3 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000